Pulmonx (LUNG) Convertible Debt (2020)

Pulmonx (LUNG) posted quarterly Convertible Debt of $29.8 million for Q3 2020.

Pulmonx (LUNG) Convertible Debt (2020) Analysis & Trends

Pulmonx (LUNG) has reported Convertible Debt for 1 consecutive years, with $29.8 million the latest figure, recorded in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	198.70 Bn	193.10 Bn	7.27 Bn
2	Stryker	125.85 Bn	122.37 Bn	4.50 Bn
3	Medtronic	118.44 Bn	109.22 Bn	6.41 Bn
4	Boston Scientific	72.64 Bn	72.10 Bn	3.85 Bn
5	Edwards Lifesciences	51.94 Bn	47.69 Bn	1.35 Bn
6	Dexcom	34.48 Bn	32.53 Bn	830.00 Mn
7	GE HealthCare Technologies	33.60 Bn	31.49 Bn	2.18 Bn
8	Koninklijke Philips	26.30 Bn	22.98 Bn	4.55 Bn
9	Steris	23.00 Bn	22.52 Bn	684.20 Mn
10	Pulmonx	93.95 Mn	24.20 Mn	-

Download Data

Date	Value
Sep 30, 2020	29.75 Mn